



## **IDT Receives Governor's Export Award for Health and Biotechnology**

***Recognition of innovation and export focus  
IDT automatically entered into National Export Awards***

**7 October 2016, Melbourne:** Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) has been awarded a Commendation in the Victorian Governor's Export Award for the Health and Biotechnology category. The award recognizes Victoria's most successful and innovative exporters and is in recognition of IDT's recent efforts to expand both its historical drug development services business, and also the development of a new proprietary specialty generic drug business.

"We are delighted to receive this award from the Victorian Governor, The Hon. Linda Dessau AM. The award is a recognition of the efforts that IDT's board and management has invested in developing and growing the business, by working to optimize the returns on the assets, people and infrastructure of the company. IDT has always been an export focused company, servicing the global pharmaceutical industry and the majority of IDT's sales are exports." said IDT's Managing Director Dr Paul MacLeman

Winners of the 12 categories including IDT are automatically placed as finalists in the Australian Export Awards – a national awards program held in November.

ENDS

For further information please contact:

IDT Australia Limited  
Dr Paul MacLeman  
Managing Director  
(03) 9801 8888

Monsoon Communications  
Rudi Michelson  
(03) 9620 3333

### About IDT

IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 Temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based at the Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.